Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Chart of the Week: ASX retail offers pockets of value in softening conditions
Why slowing consumer spending could create opportunities in overlooked retail stocks.
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,794.40 | 174.80 | -1.95% |
| CAC 40 | 7,835.31 | 129.20 | -1.62% |
| DAX 40 | 24,939.35 | 259.84 | -1.03% |
| Dow JONES (US) | 50,842.43 | 63.62 | -0.12% |
| FTSE 100 | 10,428.27 | 177.73 | -1.68% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,865.92 | 4.86 | 0.02% |
| Nikkei 225 | 68,956.72 | 2,203.00 | 3.30% |
| NZX 50 Index | 13,810.51 | 23.88 | -0.17% |
| S&P 500 | 7,655.42 | 3.88 | 0.05% |
| S&P/ASX 200 | 8,614.40 | 174.90 | -1.99% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |